In in vitro and in vivo investigations of two patients with congenital factor XIII-deficiency it was demonstrated that cryoprecipitate contains a high factor XIII-activity. Cryoprecipitate in small amounts, given as intravenous injections every 3 or 4 weeks seems to be useful as a prophylactic treatment of patients with severe haemorrhagic due to factor XHI-deficiency.